Neurofilament light chain (NfL) is a stronger biomarker for progression and brain atrophy than mutant huntingtin (mHTT) in Huntington’s disease (HD) and could be used to inform clinical trial design, specialists have reported.
News
News
Daily digests from key neurology conferences, written by on-site medical journalists.
Published: 23 May 2020